Tag: Efgartigimod alfa

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Efgartigimod alfa

argenx's Phase III pemphigus trial fails to meet endpoint - Clinical Trials Arena

Added to Collection on: 2023-12-20 18:34:39

Tags for this article:

Autoimmune diseases
Rare diseases
Antibodies
Pemphigus
Neonatal fragment crystallizable receptor
Efgartigimod alfa
Desmoglein
Immunoglobulin A
Vulgaris
Myasthenia gravis
Corticosteroid
Autoantibody

Click the tags to see associated articles and topics

View Article Details
Johnson & Johnson's IMAAVY Gets FDA Approval, Taking on Top Players in Myasthenia ...

Added to Collection on: 2025-05-22 21:50:43

Tags for this article:

Orphan drugs
Monoclonal antibodies
Nipocalimab
Myasthenia gravis
Eculizumab
GMG
Efgartigimod alfa/hyaluronidase
Efgartigimod alfa
Gravis
Neonatal fragment crystallizable receptor
Batoclimab
Rozanolixizumab
Japan
United States

Click the tags to see associated articles and topics

View Article Details
Argenx Makes $1.5B+ Play for UNP's Macrocyclic Peptides Aimed at 'Undruggable' Targets

Added to Collection on: 2025-07-01 13:30:36

Tags for this article:

Chronic inflammatory demyelinating polyneuropathy
Macrocycle
Efgartigimod alfa/hyaluronidase
Efgartigimod alfa
Peptide
Neonatal fragment crystallizable receptor
Druggability
argenx

Click the tags to see associated articles and topics

View Article Details
J&J's Nipocalimab Advances in gMG Treatment: Strategic Positioning in the Neuromuscular ...

Added to Collection on: 2025-09-19 17:43:56

Tags for this article:

Orphan drugs
Monoclonal antibodies
Autoimmune diseases
Nipocalimab
Myasthenia gravis
Neonatal fragment crystallizable receptor
GMG
Eculizumab
Gravis
Efgartigimod alfa
Food and Drug Administration
Johnson & Johnson
Johnson & Johnson's

Click the tags to see associated articles and topics

View Article Details
Myasthenia Gravis Market Outlook 2034 – Clinical Trials, Market Size, Medication ...

Added to Collection on: 2025-09-29 17:07:35

Tags for this article:

Orphan drugs
Monoclonal antibodies
Autoimmune diseases
Myasthenia gravis
Acetylcholinesterase inhibitors
Quaternary ammonium compounds
Nipocalimab
Thymectomy
Gravis
Efgartigimod alfa
MuSK protein
Pyridostigmine
Germany
Efgartigimod IV
Italy
Takeda
Kyverna Therapeutics
Dianthus Therapeutics
France
Japan
United States
United Kingdom
cartesian therapeutics
COUR Pharmaceuticals
AstraZeneca
HOFFMANN - LA ROCHE
Spain
Regeneron Pharmaceuticals

Click the tags to see associated articles and topics

View Article Details
Book a Demo